Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $5.02 and traded as high as $5.93. Astria Therapeutics shares last traded at $5.81, with a volume of 188,854 shares.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on the company. Wedbush reiterated an "outperform" rating and issued a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $47.00 price objective on shares of Astria Therapeutics in a report on Wednesday, May 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Friday, June 13th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $30.00.
View Our Latest Stock Report on Astria Therapeutics
Astria Therapeutics Trading Up 3.4%
The company has a market capitalization of $361.72 million, a PE ratio of -3.43 and a beta of 0.41. The firm has a fifty day moving average of $5.07 and a two-hundred day moving average of $6.07.
Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.10). On average, equities analysts expect that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.
Institutional Investors Weigh In On Astria Therapeutics
Institutional investors have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS purchased a new stake in Astria Therapeutics during the 4th quarter valued at about $41,000. Tower Research Capital LLC TRC boosted its holdings in Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 2,766 shares during the period. BNP Paribas Financial Markets purchased a new stake in Astria Therapeutics during the 4th quarter valued at about $50,000. Virtus ETF Advisers LLC purchased a new stake in Astria Therapeutics in the 4th quarter worth approximately $65,000. Finally, GAMMA Investing LLC lifted its holdings in Astria Therapeutics by 1,127.4% in the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock worth $46,000 after buying an additional 7,971 shares during the period. 98.98% of the stock is currently owned by hedge funds and other institutional investors.
Astria Therapeutics Company Profile
(
Get Free Report)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Further Reading
Before you consider Astria Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astria Therapeutics wasn't on the list.
While Astria Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.